Poolbeg Pharma PLC (POLB.L) LSE
7.40
+0.84(+12.80%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
7.40
+0.84(+12.80%)
Currency In GBp
Address
Queen Mary BioEnterprises Innovation Ctr
London, E1 2AX
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 7183 1499
Sector
Healthcare
Industry
Biotechnology
Employees
15
First IPO Date
July 19, 2021
| Name | Title | Pay | Year Born |
| Jeremy Skillington | Chief Executive Officer & Director | 332,000 | 1971 |
| Cathal Martin Friel | Executive Chairman of The Board | 151,000 | 1964 |
| Ian O'Connell | Chief Financial Officer & Director | 235,000 | 1987 |
| Carol Dalton | Vice President of Investor Relations & Public Relations | 0 | N/A |
| Ross Crockett | Group Financial Controller | 0 | N/A |
| Liam Tremble | Principal Scientist | 0 | N/A |
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.